Analysts Expect Crispr Therapeutics AG (CRSP) Will Announce Earnings of -$0.92 Per Share

Equities research analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings of ($0.92) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($1.01). Crispr Therapeutics reported earnings per share of ($0.82) in the same quarter last year, which would suggest a negative year over year growth rate of 12.2%. The business is scheduled to issue its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($3.82) per share for the current fiscal year, with EPS estimates ranging from ($4.18) to ($3.17). For the next year, analysts anticipate that the business will post earnings of ($4.26) per share, with EPS estimates ranging from ($5.04) to ($3.24). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $1.50 million. Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The business’s revenue for the quarter was down 78.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.62) earnings per share.



CRSP has been the subject of a number of recent analyst reports. BidaskClub cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, April 29th. Goldman Sachs Group cut shares of Crispr Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $78.00 to $40.00 in a research report on Monday, January 28th. William Blair initiated coverage on shares of Crispr Therapeutics in a research report on Wednesday, March 13th. They set a “market perform” rating for the company. Finally, BTIG Research initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, February 7th. They set a “buy” rating and a $43.00 price target for the company. Three research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $47.64.

CRSP traded down $0.61 during midday trading on Friday, hitting $38.83. 296,800 shares of the company traded hands, compared to its average volume of 715,573. The company has a quick ratio of 15.84, a current ratio of 15.84 and a debt-to-equity ratio of 0.08. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -11.29 and a beta of 3.11. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $73.90.

In related news, CEO Samarth Kulkarni sold 20,000 shares of Crispr Therapeutics stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $42.03, for a total value of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares in the company, valued at $7,840,360.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Rodger Novak sold 85,220 shares of Crispr Therapeutics stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $40.40, for a total transaction of $3,442,888.00. Following the completion of the transaction, the president now owns 1,024,534 shares of the company’s stock, valued at approximately $41,391,173.60. The disclosure for this sale can be found here. Insiders sold 128,693 shares of company stock valued at $5,222,495 in the last 90 days. Company insiders own 37.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in shares of Crispr Therapeutics by 11.3% in the third quarter. Bank of New York Mellon Corp now owns 34,618 shares of the company’s stock valued at $1,535,000 after purchasing an additional 3,514 shares in the last quarter. FMR LLC grew its holdings in shares of Crispr Therapeutics by 5.7% in the fourth quarter. FMR LLC now owns 315,836 shares of the company’s stock valued at $9,024,000 after purchasing an additional 16,900 shares in the last quarter. Shelton Capital Management grew its holdings in shares of Crispr Therapeutics by 70.7% in the fourth quarter. Shelton Capital Management now owns 12,800 shares of the company’s stock valued at $366,000 after purchasing an additional 5,300 shares in the last quarter. Capital Investment Advisory Services LLC grew its holdings in shares of Crispr Therapeutics by 49.6% in the fourth quarter. Capital Investment Advisory Services LLC now owns 25,279 shares of the company’s stock valued at $722,000 after purchasing an additional 8,376 shares in the last quarter. Finally, Creative Planning grew its holdings in shares of Crispr Therapeutics by 34.9% in the fourth quarter. Creative Planning now owns 14,791 shares of the company’s stock valued at $423,000 after purchasing an additional 3,827 shares in the last quarter. Hedge funds and other institutional investors own 43.71% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.